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ABSTRACT
Age-related macular degeneration (AMD) is a reason of severe vision loss worldwide.
Pazopanib is a multitargeted tyrosine kinase inhibitor drug that can reduce neovascularization by
mainly acting on vascular endothelial growth factor receptor (VEGFR). An intraocular injection
to posterior segment of eye of anti-VEGF agent at present represents the cornerstone of therapies
for AMD. However, challenges in targeting and delivering drug to eye’s posterior segment well
as difficulties arising from repetitive frequent intraocular injections, which requires novel drug
delivery method. In this study, pazopanib loaded PLGA‐NPs were prepared and the studied
formulation had particle size of 132.1 ± 1.4 nm with PDI of 0.125 ±0.023 and 0.004± 0.13 mV
for zeta potential. Entrapment efficiency was found 33.9 ± 2.5%. In vitro drug release study
showed sustained drug lease. In vitro characterization in human retinal pigmented epithelial cell
line described MTT assay, cellular uptake, wound scratch and anti-VEGF assay, which indicated
that nanoparticles formulation had less toxicity, higher uptake, had superior anti-angiogenic
potential and showed prolonged inhibition of VEGF activity. Therefore, pazopanib loaded PLGA
nanoparticles were successfully developed, characterized and demonstrated its treatment of
AMD.
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INTRODUCTION
Age-related macular degeneration (AMD) is a major cause of intractable and severe
vision loss and blindness in developed countries (Pennington, DeAngelis, & vision, 2016).
Vascular endothelial growth factor (VEGF) is an important stimulator in a model of retinal and
choroidal neovascularization (Aiello et al., 1995; Kwak, Okamoto, Wood, Campochiaro, &
science, 2000; Miller et al., 1994; Ozaki et al., 2000), which significantly reduced neovascular
activity and vascular permeability in ocular tissues (Cheng et al., 2012; Shienbaum et al., 2012).
Pazopanib (Fig 1.) is a multi-tyrosine kinase inhibitor (TKI) compound with low
solubility and high permeability, recently approved by the FDA, designed to target growth factor
receptors with integral tyrosine activities involved in angiogenesis thus reduce
neovascularization mainly acting on vascular endothelial growth factor receptor (VEGFR)
(Khurana, P Patel, Agrahari, Pal, & K Mitra, 2014). Treatment of using pazopanib for patients
with advanced cell carcinoma and soft tissue sarcoma shows promising results (Sternberg et al.,
2010; van der Graaf et al., 2012). Recent studies show, in preclinical pazopanib has the potential
of mitigating retinal vascular leukocytosis, and leakage (de la Fuente et al., 2010; Malavade,
2016;
Thakur, Scheinman, Rao, & Kompella, 2011).Even though the most common clinical
treatment of AMD related diseases is to targeting VEGF but these treatments are not free from
side effects. Also, requirement of frequent injection increases the chances of potential
haemorrhaging, infection and retinal detachment (Dejana, Tournier-Lasserve, & Weinstein,
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2009; Sampat & Garg, 2010; Weis & Cheresh, 2005; Y. Zhang et al., 2008). Thus,
administration of controlled drug delivery system is to be sought for addressing this problem.
PLGA shows immense potential for sustained drug release, favourable degradation
characteristics at nanoscale without any surgical intervention and demonstrated low toxicity and
few side effects (de la Fuente et al., 2010; Hirani et al., 2016; Malavade, 2016). Bourges et al.
(Bourges et al., 2003) proved the efficacy of intravitreally administered PLA nanoparticles
(loaded with Rh-6G and Nile red fluorochromes) in retinal drug delivery in rats. The authors
found after 18–24 hours’ intravitreal injection, the nanoparticles were localized within the RPE
cells and showed sustained release of the drug around four months after injection.
Therefore, in this study pazopanib loaded PLGA NPs were prepared and characterized
via various physicochemical techniques like Particle size, Zeta potential, TEM, entrapment
efficiency, in vitro drug release and in-vitro studies such as cytotoxicity, cellular uptake, wound
scratch and anti-VEGF assay.
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LITERATURE REVIEW
Age-related macular degeneration
Age-related macular degeneration (AMD) is a reason of severe vision loss in developed
countries especially among elderly people. AMD has three stages early stage and intermediate
stage are determined by the presence of drusen while the late stage is determined by the number
and size of the drusen. AMD is including two types dry and wet AMD. Even though wet AMD is
less frequent, it is leading cause of 90% of acute vision loss. There are couple of treatments
available at the same time they come with their own drawbacks. Laser therapy can destroy
abnormal blood vessels, but it might destroy healthy tissues as well; intravitreal injection, there
are already 4 marketed drugs such as Lecentis ™ (Ranibizumab), Macugen®(Pegaptanib), but
they require frequent injection not patient friendly (Makhson et al., 2006; Michalska-Małecka,
Kabiesz, Nowak, & Śpiewak, 2015).
Pazopanib
Pazopanib (Fig 1.) is a multi-tyrosine kinase inhibitor (TKI) compound with low
solubility and high permeability, recently approved by the FDA, designed to target growth factor
receptors with integral tyrosine activities involved in angiogenesis thus reduce
neovascularization mainly acting on vascular endothelial growth factor receptor (VEGFR)
(Khurana, P Patel, Agrahari, Pal, & K Mitra, 2014) Treatment using pazopanib for patients with
advanced cell carcinoma and soft tissue sarcoma shows promising results (Sternberg et al., 2010)
(Van Der Graaf et al., 2012). Recent studies show, in preclinical pazopanib has the potential of
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mitigating diabetic retinal vascular leukocytosis, and leakage (de la Fuente et al., 2010; Thakur,
Scheinman, Rao, & Kompella, 2011).

Figure 1: Structure of pazopanib (Isham et al., 2013)
Cost-Effectiveness of Pazopanib
As indicated by a cost – effectiveness analysis, pazopanib had essentially bring down expenses
and comparable advantages compared with other VEGF-inhibitors as leading position to provide
treatment for patients with mRCC (Purmonen & research, 2011). Pazopanib is less expensive
contrasted with sunitinib (Park et al., 2009).
VEGF
VEGF plays a vital role for not only vascular permeability but also angiogenesis Cascade
of molecular and cellular events are responsible for the neovascularization, especially triggered
by VEGF (BURDITT, Caird, & Draper, 1968; Frank, 2015; Shah, 2008; W. Zhang, Liu, AlShabrawey, Caldwell, & Caldwell, 2011). In inflamed and vascularized cornea expression of
VEGFR is highly upregulated. AS endothelial cells are one of the main sources of VEGF in
cornea, growth acceleration, migration and survival of endothelial cells are characterized by the
VEGF effect. Promotion of the graft survival of the cornea can be done using blockage of VEGF.
VEGF is the ligand of VEGFR1 and VEGFR2, tyrosine receptors and especially VEGFR2 is
4

responsible for pertaining to the regulation of proangiogenic factors. Even though the most
common clinical treatment of ocular neovascular related diseases is to targeting VEGF but these
treatments are not free from side effects. Also, requirement of frequent injection increases the
chances of potential haemorrhaging, infection and retinal detachment (Dejana, TournierLasserve, & Weinstein, 2009; Sampat & Garg, 2010; Weis & Cheresh, 2005; Y. Zhang et al.,
2008).
Nanotechnology
The term nanotechnology is widely used in the realm of applied physics. However,
recently, this term has entered in the medicine field as the nanomedicine. Nanotechnology
facilitated the alteration of physical properties to meetup the needs based on application at
precision level. Active pharmaceutical ingredients (API) can be encapsulated in the
nanostructure with high efficiency and low toxicity (Hirani et al., 2016). Therefore, the
utilization of pazopanib on a nanoscale for the treatment of diabetic retinopathy can show a
promising therapeutic benefit with reduced toxicity and undesirable side effects. The entrapment
of pazopanib within nanoparticles will demonstrate sustained release at the desired site.
PLGA
Poly lactic-co-glycolic acid (PLGA), FDA-approved biodegradable polymer has been
immensely studying as a carrier for drugs, proteins, DNA, RNA and peptides, due to its high
strength and biocompatibility (Bouissou, Rouse, Price, & Van der Walle, 2006; Jain, 2000; Ruhé
et al., 2006). PLGA shows immense potential for sustained drug release, favourable degradation
characteristics at nanoscale without any surgical intervention and demonstrated low toxicity and
few side effects (de la Fuente et al., 2010; Hirani et al., 2016; Malavade, 2016). The main
advantages of PLGA is to achieve desired dosage, physical properties of the polymer can be
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tuned by controlling molecular weight ratio of lactide to glycol ide (Allison, 2008; Mohamed &
van der Walle, 2008; Mundargi, Babu, Rangaswamy, Patel, & Aminabhavi, 2008). Additionally,
that PLGA can easily be formulated into the drug carrying devices even in nanoscale, which can
encapsulate a wide range of drugs, peptides or proteins(Makadia & Siegel, 2011). This allows
particles around 200 nm to be localized in the retinal pigment epithelium (RPE) with increase
solubility and surface area of nanoparticles (Huang, Presley, Chimento, Curcio, & Johnson,
2007).
PLGA Nanoparticle
PLGA NPs have been shown to have low cytotoxicity and few side effects (Hirani et al.,
2016) (Geldenhuys, Mbimba, Bui, Harrison, & Sutariya, 2011). PLGA NPs also provide
sustained release of encapsulated molecules (Carroll et al., 2010). Bourges et al. (Bourges et al.,
2003) proved the efficacy of intravitreally administered PLA nanoparticles (loaded with Rh-6G
and Nile red fluorochromes) in retinal drug delivery in rats. The authors found after 18–24 hours’
intravitreal injection, the nanoparticles were localized within the RPE cells and showed sustained
release of the drug around four months after injection. Park et al. (Park et al., 2009) found that
K5-NP mediates efficient and sustained K5 expression in the retina and has therapeutic potential
for diabetic retinopathy.

6

MATERIALS AND METHODS
Materials
Pazopanib (PZ) was ordered from Selleck Chemicals (Houston, TX, USA). Poly (DLlactide-co-glycolide) (50:50 lactide glycolide/MW 19000) (PLGA) was obtained from Acros
Organics (NJ, USA). Dialysis membrane (MWCO: 10,000 Da), Sodium hydroxide and
Coumarin 6 dye were purchased from Sigma Aldrich (St. Louis, MO). Fetal Bovine Serum
(FBS) and Penicillin-streptomycin (10,000 U/ml) were purchased from Gibco Thermo Fisher
Scientific, USA. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide salt (MTT
reagent), and nucleus stain DAPI (4′,6-diamidino-2-phenylindole) were purchased from Tocris
Bioscience (MN, USA). Cell maskTM deep red plasma stain was purchased from molecular
probes, InvitrogenTM Thermo Fisher Scientific, USA. Pierce BCA protein assay kit and
Invitrogen™ eBioscience™ Human VEGF-A Platinum ELISA Kit were purchased from fisher
scientific, USA. ARPE-19, a human retinal pigment epithelial cell line (ATCC® CRL2302™)
and Dulbecco’s Modification of Eagle’s Medium F 12 (DMEM F12) were purchased from
American Type Culture Collection (ATCC) (VA, USA). Cell culture Phosphate Buffer Saline
(1X) (PBS) was ordered from Corning Cellgro (Manassas, VA). Trypsin (0.05%) was ordered
from Thermo Fisher (Lansing, MI). All other chemicals used were of analytical reagent grade
and were used without any further purification.
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Cell Culture
ARPE-19, a human retinal pigment epithelial cells (ATCC® CRL2302™) were grown
and maintained in DMEM F12 medium supplemented with 10% v/v FBS and 1% 10,000 U/ml
penicillin-streptomycin antibiotics. The cell cultures were incubated in a humidified atmosphere
of 5% CO2 at 37 °C temperature.
Preparation of Pazopanib loaded PLGA NPs
Pazopanib-loaded PLGA nanoparticles were formulated via o/w emulsion solvent
evaporation method (Patel et al., 2018). Briefly, Pazopanib (PZ) and PLGA (weight ratio: 1:7) as
organic phase were dissolved in 1 ml of DMSO: Acetone (1:9). PLGA/PZ solution was slowly
added drop wise with an 23G needle to 2 ml of deionized water, which pH was previously
adjusted with sodium hydroxide to a pH of 9 while stirring at 700 rpm at room temperature. Then
left to stir for overnight to evaporate solvent on magnetic stirrer (Thermo Fisher, Lansing, MI).
The prepared nanoparticles were centrifuged at 5000 rpm for 5 min to remove the unentrapped
drug followed by centrifugation at 18000 rpm for 20 min to collect the nanoparticulate pellet
from the bottom of the Eppendorf tubes at room temperature. The collected pellet was washed
thrice with distilled water and resuspended in saline. Blank nanoparticles and Coumarin 6 loaded
nanoparticles (only dye without drug) were formulated in same manner.
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Figure 2: Graphical representation of preparation method of PZ-NPs
Particle size and Zeta potential
Particle size of nanoparticles (in nm) was determined using principle of dynamic light
scattering (DLS) (Yewale et al., 2018). Light source was 633 nm He-Ne laser and scattering
angle was 90° (Nano ZS90, Malvern Instruments Ltd., UK, Zeta Sizer Software Ver. 7.10).
Analysis was carried out in triplicate at 25 °C temperature after appropriate dilution with double
distilled water. The results were reported as Z-average along with polydispersity index (PDI).
Zeta potential values were obtained using Smoluchowski equation which takes into
account electrophoretic mobility of the particles and 90° back-scatter (Patil et al., 2016). The
nanoparticles were sufficiently diluted with double distilled water and analysis was carried out in
triplicate using zeta cuvette and ZetaSizer NanoZS 90 (Malvern Instruments Ltd., UK, Zeta Sizer
software Ver. 7.10).
Transmission Electron Microscope
Morphology, size, and shape of the PZ loaded nanoparticle were ascertained by
transmission electron microscope (TEM) (JEOL JEM 1400 electron microscope with Gaton
camera, Peabody, MA, USA). Sufficient amount of nanoparticle sample was placed on EMS
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formvar support film square grid, 200 Cu and allowed to air dry for 10 min. Subsequently, it was
stained with 2% w/v phosphotungstic acid. The samples were examined at accelerating voltage
of about 120 kV with 40,000 magnification.
Entrapment efficiency
For determination of entrapment efficiency, the reconstituted nanoparticles were treated
with methanol to extract the loaded drug and were analysed by high performance liquid
chromatography (HPLC) (Agilent 1100 HPLC System) 260 nm (λmax) using C18 column. The
mobile phase was 45% ammonium acetate with pH7, 55% of organic solvent is mixture of
methanol, acetonitrile (30:70, v/v) at a flow rate of 1 ml/min.
𝐴𝑐𝑡𝑢𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑒𝑑 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠

% Entrapment efficiency =𝐴𝑐𝑡𝑢𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑢𝑠𝑒𝑑 𝑓𝑜𝑟 𝑃𝑍−𝑁𝑃𝑠 𝑝𝑟𝑒𝑝𝑎𝑟𝑎𝑡𝑖𝑜𝑛 * 100
In vitro drug release study
The in vitro release study was carried out triplicate for both the free pazopanib solution as
well as PZ-NPs (MWCO: 10,000 Da) in 20 mL of release medium PBS (pH 7.4) containing
0.1% (v/v) Tween 80 (C. Zhang, Qineng, & Zhang, 2004) at 35 ± 2°C with continuous stirring at
150 rpm. Briefly, Free pazopanib solution (1 mg/mL) was prepared by dissolving pazopanib
drug in DMSO. Samples were taken 0.5 mL at 0.25, 0.5, 1, 2, 4, 6, 12, 24, 48, 72, 96, 120, 144
and 168 h. The volumes were made up with fresh release medium after each sampling. The
Quantitative analysis of PZ in a sample was determined by HPLC at 260 nm to determine the
cumulative percent release of drug at each time point.
Cytotoxicity study
The MTT assay was utilized to determine the cytotoxicity of the PZ-NPs in comparison
to free pazopanib drug solution in human retinal pigment epithelial (ARPE-19) cells. Cells were
seeded at a cell count of 5000 cells/well on a 96 well plate (Corning, New York) in 200 μl of 1X
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Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% v/v FBS and were
incubated at 37 °C, 5% carbon dioxide atmosphere for 24hours (P. Bhatt, Khatri, Kumar,
Baradia, & Misra, 2015). Formulations and pure drug solution were diluted with serum free
DMEM F12 medium to prepare various concentrations of PZ. After 24 h of growth, the cells
were treated with both free drug solution and pazopanib nanoparticles then the treatment was left
to incubate for 4 h. After 4 h of incubation, fresh complete DMEM medium containing 10% FBS
replaced with the treatment after washing the cells with sterile 1X PBS. After 24 h & 48 h, the
cells were washed and 100 μl of MTT reagent (1 mg/mL) solution was added to each well and
kept at incubator (37 °C, 5% CO2) for 4 hours. Then added 100 μl of dimethyl-sulfoxide
(Himedia, Mumbai). Intensity of colour of the dissolved formazan crystals was measured via
microtiter plate reader (Spectra MAX 190, Molecular Devices, California, USA) at a wavelength
of 595 nm. Cells treated with DMEM F12 and 0.1% Triton X were defined as negative and
positive control, respectively. Cell viability was given relative to that of the negative control. PZ
were calculated graphically from concentration vs viability curves, considering the optical
density of control well as 100% viable.
Cellular uptake
Confocal microscopy was carried out to detect the uptake of the NPs by ARPE-19 cells.
Drug formulation, coumarin formulation and blank were prepared as mentioned above (Priyanka
Bhatt, Lalani, Mashru, & Misra, 2016). Cells were seeded at a density of 2X105 cells per well
onto 6-well plate and incubated for a day to achieve 70% confluency. Cells were washed with
PBS three times then treated with flowing formulations, drug nanoparticles, coumarin loaded
nanoparticles and blank nanoparticles. After 4 h incubation, the medium of well aspirated and
washed thrice with PBS and fixed with 4% paraformaldehyde. Then DAPI was added to the cells
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for nuclear staining followed by Cell-maskTM deep red plasma stain for membrane staining.
Fluorescence microscopy images were obtained using a FV1200 Confocal Microscope
(Olympus, Tokyo, Japan) at 60x magnification.
Wound scratch assay
Wound healing assay was performed to test the inhibitory effect of PZ and its formulation
on VEGF165 (rhVEGF; R&D Systems) induced angiogenesis (Espana-Serrano & Chougule,
2016), (Goel & Gude, 2011). ARPE-19 cells were seeded in 24 well plates and allowed to reach
80% confluency. Pipette tip was used to create wounds by remove cell monolayer as a strip.
Wounds were around 300μm with average size and within 5% width variation was considered
for the study. Sterile PBS was used to wash the wounds twice to ensure removal of partly
adhered cells on the plates due to wound. The cells were treated with drug formulation and PZNPs formulation in incomplete media at 1µM and 10µM concentration. Cell migration was
observed by microscopy (ZEISS inverted phase contrast microscope, Axicom 506 mono and
Axicom MRC5-ZEN2pro software) and quantified via measuring the area covered by the cells,
which migrated from the wound edges using ImageJ software. The wells treated with complete
medium and VEFG separately acted as reference and controls respectively. After 48 hours
incubation at 37 °C in CO2 incubator (5%), treatments were removed, and the cells were washed
with sterile PBS thrice. Images were taken after fixing with 70% ethanol, and measured wound
width using images captured by microscope. Width of the untreated group at 0 h was considered
100% and relatively % wound recovery were compared.
Anti VEGF ELISA/VEGF-A inhibition
ARPE19 cells were seeded in 24 well plate at density of 5 x 104 cells/mL for 24 hours to
achieve confluent. Then treated with treatment groups free drug solution and PZ-NPs
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formulation. Each treatment group concentration was at 10µM and further incubated for a total
period of 72 hours. Quantification of the secreted VEGF in the culture media was performed by
ELISA method using Human VEGF-A Platinum ELISA Kit following manufacturer’s
instructions (Kim & Suh, 2017), (Kathleen, Shannon, Iqbal, Yashwant, & Vijaykumar, 2019).
Pierce BCA protein assay kit was used to estimate the protein content in the cells after collecting
cell lysate and the via normalizing VEGF secretion to total protein. Samples were read using
plate reader at 450 nm and 550 nm absorbances respectively and the differences were recorded.
Then using standard curve to calculate the inhibition of VEGF secretion.
Statistical analysis
All studies were performed in triplicate and data are represented as mean ± standard
deviation. ANOVA, Student’s t-test and GraphPad Prism (version 6, USA) were used to
statistical data analysis. P value < 0.05 was considered significant.
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RESULT
Particle size and Zeta potential
The size and PDI of PZ-NPs were determined via DLS technique and the size was found
to be of 132.1 ± 1.4 nm with PDI of 0.125 ±0.023. The low PDI of the PZ-NPs showed the
dispersion homogeneity and uniform distribution of particle size of the nanoparticles. The mean
zeta potential of PZ-NPs was investigated via Malvern Zetasizer Nano ZS90 and was -20.12 ±
2.7 mV for the PZ-NPs. Figure 2(A) shows Z-average along with the correlation functional plots
for PZ-NPs.

Figure 3: A. Z-average of PZ-NPs along with the correlation functional plots, B. TEM image of
PZ-NPs at accelerating voltage of 120 kV with 40,000X magnification.
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Transmission Electron Microscope
TEM images of PZ-NPs showed particle size around 135 nm. The particle size different
between the size obtained via DLS and TEM, this difference can be easily recognized since DLS
records the hydrodynamic diameter of the particles while TEM records the size was obtained of
the particle fixed in grid. TEM images (figure 2 (B)) demonstrated that PZ-NPs was uniformly
spherical and of regular shape comes along with a narrow size distribution.
Entrapment efficiency
Encapsulation efficiency (EE) was determined from standard curve developed with
varying pazopanib concentrations in methanol. EE was found 33.9 ± 2.5%. HPLC was used to
determine the encapsulation efficiency of PZ by comparing the peak in methanol to standard
dilutions of PZ in HPLC grade methanol at 260 nm (λmax).
In vitro drug release study
The in-vitro release study of free PZ and PZ-NPs was evaluated via dialysis method using
PBS (pH 7.4) as release media to mimic the physiological condition and condition inside the
posterior segment of eye, for 7 days at 37 °C. Free PZ was rapidly released and reached a
cumulative release of nearly 100 % of the total drug within 12 hours. However, PZ-NPs released
longer time compared with free drug (Fig. 4) showed that the encapsulated achieved a sustained
release.
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Figure 4: In vitro release of PZ from PZ solution, PZ-NPs upto 7 days at 37 °C in phosphate
buffer saline at pH 7.4

Cytotoxicity study
The cytotoxicity of the free PZ solution and PZ-NPs was evaluated by MTT assay in
human retinal pigmented epithelium (ARPE19) cell line. The cytotoxicity of various PZ
formulations showed a concentration- dependent pattern with various concentrations (0, 0.001,
0.01, 0.1, 1, 10 and 20 μM) of PZ solution, blank NPs and PZ-NPs in triplicates for 24 and 48
hours. Results indicated that the viability of cells was greater than 87% for PZ-NPs and blank
nanoparticles at 10 µM and 20 µM concentration tested whereas, for drug solution viability was
found to be 83% and 71% respectively at above concentration, thus indicating cell compatibility
of the formulation (figure 7).
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Figure 5: % cell viability plots at various concentrations of PZ drug solution and PZ NPs at (A)
24 h and (B) 48 h in ARPE 19 cell line.
Cellular uptake
Coumarin-6 loaded PLGA NPs is used for determining the uptake of NPs in ARPE 19
cells. Coumarin-6 loaded PLGA NPs were prepared as same method as PZ-NPs by loading
Coumarin-6 dye instead of PZ drug. As shown in Figure 6, the cellular uptake of coumarin 6loaded PLGA NPs exhibited a time-dependent mode within 2 hours at 37 °C as following order
blue cell nucleus stained by DAPI, red fluorescence exhibiting cell membrane stained with Cell
Mask Deep Red stain, green fluorescence depicting cytoplasm of the cells which uptake
17

coumarin-6 loaded NPs and the merged images on the last panel. The cellular uptake of the NPs
is likely to have occurred throughout endocytosis. Green fluorescence has been not observed in
untreated cells.

Figure 6: Cellular uptake of coumarin 6-loaded PLGA NPs into ARPE 19 cells within 2 h of
time frame at 37 °C
Wound scratch assay
Wound scratch assay was carried out to detect the migration of cell. Fig. 7 (A) showed
that the untreated well (control) presented fully wound recovery same as initial well reference,
while concentration dependent of wound recovery was observed from the PZ-NPs treatment
group. Fig. 7 (B) exhibits the lowest wound recovery for the highest concentration of PZ in
PLGA NPs i.e. at 10 µM concentration, the % wound recovered was 52 ± 3.6% while 62 ± 2.3%
for 1 µM
18

concentration. Also, at equimolar concentration of treatment of PZ drug solution and PZ-NPs
treatment, the % recovery of the wound of PZ-NPs significantly lower than PZ drug solution
indicating the better performance of PZ-NPs formulation in inhibiting cell proliferation. Fig. 7
(A) presented the highest wound recovery for the 100 nM of VEGF165 (rhVEGF; R&D
Systems). However, co-treatment of PZ-NPs formulation with VEGF165 could hinder the
VEGF165’s activity as well as inhibited angiogenic manifestations induced by VEGF in ARPE
19 cells and did not significantly improved the % wound recovery. Based on these results PZNPs efficiently and selectively inhibits VEGF-induced angiogenesis in ARPE 19 cells.
Anti VEGF ELISA
The effect of the PZ drug solution and PZ-NPs on secretion of VEGF was studied on
ARPE-19 cells. Human VEGF-A Elisa kit was used to measure the amount of VEGF-A after 12,
24, 48 and 72 h of treatment. %VEGF secretion values are illustrated (Figure 8) taking the
control group value as 100%. Free PZ solution significantly decreased VEGF secretion
throughout all treatment groups. PZ-NPs formulation have similar effects on VEGF-A secretion.
ELISA exhibited noticeably (P < 0.05) reduced VEGF protein levels after exposure to PZ-NPs in
ARPE19 (10 µM) at 24, 48, and 72 hours in comparison with control cells and cells treated with
drug solution.
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Figure 7: (A) Wound healing images in presence of PZ pure drug (PZD), VEGF 165 and various
concentration of PZ-NPs (PZF) (scale bar). (B) Percent wound covered after 48 h in comparison
to untreated wound at 0 h for PZD and PZF at various concentrations. ** P < 0
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Figure 8: % VEGF expression in ARPE-19 cells treated with PZ drug solution and PZ-NPs for
different time point determined using ELISA assay method (mean ± SD, n =3) p<0.01.
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DISCUSSION
The pazopanib encapsulated PLGA NPs was in nanoscale and have a proper size 135 nm
that easily penetrate the cell. TEM images showed that the nanoparticles were spherical in shape
without aggregated. The MTT results indicate that the nanoparticulate formulation was less
cytotoxic than the free pazopanib solution due to using of PLGA, which is FDA-approved and
most widely used biocompatible polymer in drug delivery. The cellular uptake exhibited a timedependent mode showing increase in the fluorescence of the nanoparticles demonstrates that the
mechanism of cellular uptake likely to be mediated by interacting with receptor and as the
ARPE-19 cells express VEGF receptor, the cellular uptake expecting endocytosis as the most
rational mechanism. Angiogenesis involves number of synchronized events such as cell
proliferation, cell migration, and cell morphogenesis. Wound scratch migration assay was used
to study the in vitro angiogenesis. Assessment of the migration of cells offers a quantitative
evaluation of inhibition of growth of cell (via measuring the wound recovery) in the presence of
PZ formulations. This study provides an estimate of formulation behaviour once it reaches the
action site in vivo and it is vital in vitro study to extrapolate cells behaviour in presence of
formulation. The formulation with least efficacy will present higher recovery, wound coverage
and vice versa. As mentioned earlier, there was concentration-dependent proliferation of the cell
inhibition observed for the cells treated with nanoparticle formulation. To indicate that VEGF
activity was inhibited, the ARPE-19 cells were treated with exogenous VEGF as well as
formulation and wound recovery was observed. Effectiveness of the drug in the nanoparticle
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formulation has been confirmed via the inhibition of cell migration in those co-treatment stage.
Finally, ELISA was carried out to test the VEGF expression levels in the cell line upon the
various treatment groups. Although from both drug solution and nanoparticles treatment group,
the drug solution form showed strongest inhibition of VEGF levels at initial time point of 12 hr
compared to the nanoparticles, it exhibited weak control at subsequent time points. This may be
correlated to initial high level of free drug available to the cells due to solution form as well as
the release profile of the formulation. However, in case of nanoparticle formulation, initially
there was low level of VEGF control and which became stronger as the drug release from the
matrix over longer period of time. At the end of 72 hours, the expression levels for the
nanoparticles were almost 60% whereas those cells treated with free drug solution displayed no
inhibition. Hence, a point to be noted that the higher inhibitory effect of nanoparticle formulation
compared to its free drug solution. This may be due to slower release of drug from the
nanoparticle matrix as compared to its free drug solution. Altogether it can be concluded that
PLGA NPs provided a sustained release formulation of pazopanib for longer duration.
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CONCLUSION
Pazopanib-loaded nanoparticles were successfully developed, characterized and in-vitro
studies tested in human ocular epithelial cell line demonstrating its usefulness in ocular delivery
to treat AMD. As a prominent requirement for intravitreal delivery to be effective is delivering
sufficient dose of therapeutic at site of action along with sustained release.
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